CG101 + artificial tear

CG101 + artificial tear is a combination therapy being investigated for the treatment of dry eye syndrome. This combination consists of CG101 eye drops (at either low or high doses) used together with artificial tears. According to the search results, this combination is currently being studied in a clinical trial (NCT06792903) at the Eye & ENT Hospital of Fudan University in Shanghai, China. The trial is a single-center, randomized, double-blind, placebo-controlled, cross-over study designed to evaluate the effectiveness and safety of CG101 eye drops for dry eye syndrome treatment. The study involves three treatment groups: CG101 low dose + artificial tear, CG101 high dose + artificial tear, and placebo + artificial tear (as control). The treatment period lasts for 84 days, with participants randomly assigned to different sequences. While the mechanism of action of CG101 is not detailed, artificial tears are commonly used to protect and lubricate mucous membranes and relieve eye dryness and irritation. Artificial tears typically contain ingredients such as carboxymethylcellulose, dextran, glycerin, hypromellose, polyethylene glycol 400, polysorbate, polyvinyl alcohol, povidone, or propylene glycol. The clinical trial for CG101 + artificial tear appears to be in Phase 1. The study started in January 2025 and is currently recruiting participants.